Please assess the completion status of the following clinical trial:

Trial Title: Reactogenicity, Safety and Immunogenicity of QazCovid-in® COVID-19 Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Availability of signed and dated informed consent of the volunteer to participate in the study.~* Healthy male and female volunteers aged 18-50 and 50 and above.~* Ability and voluntary desire to independently keep records in the Self-Observation Diary, as well as to carry out all the repeated visits provided for in the study for control medical observation.~* The voluntary desire of females to use methods of reliable contraception throughout the entire period of their participation in the study.~* Negative results for IgM and IgG antibodies to SARS-CoV-2.~* Absence of COVID-19 diagnosis in history.~* Absence in the last 14 days of close contact with persons suspected of being infected with SARS-CoV-2, or persons whose diagnosis of COVID-19 has been confirmed with laboratory.~* Negative test results for human immunodeficiency virus (HIV), hepatitis B and hepatitis C.~Exclusion Criteria:~* Aggravated allergic history, drug intolerance, including hypersensitivity to any of the components of the study drug, as well as a history of serious adverse events during vaccine administration (such as allergic reactions, respiratory failure, angioedema, abdominal pain).~* Acute illness with fever (body temperature ≥37.1°C) at the time of screening/randomization.~* Chronic alcohol and/or drug use in history.~* Clinically significant deviations from normal values during laboratory and/or imaging at screening.~* Women with a positive urine pregnancy test.~* Simultaneous treatment with immunosuppressive drugs, including corticosteroids (2 weeks) 4 weeks prior to study drug administration.~* Acute or chronic clinically significant lesions of the lungs, cardiovascular system, gastrointestinal tract, liver, blood system, skin, endocrine, neurological and psychiatric diseases or impaired renal function (asthma, diabetes, thyroid disease, arrhythmia, myocardial infarction, severe hypertension not controlled by drugs, etc.), identified based on medical history, physical examination or clinical laboratory tests that, according to the researcher, may affect the study result.~* Disruption of platelets or other blood clotting disorders, which may cause contraindications to intramuscular administration.~* Leukemia or neoplasm in history.~* Persons with autoimmune diseases.~* Volunteers who received antiviral drugs, immunoglobulin's or blood transfusions or any other investigational drug within 4 weeks prior to study drug administration;~* Volunteers who received anti-inflammatory drugs 2 days before study drug administration;~* Participation in any other clinical research within the last 3 months.~* Volunteers with a concern that they will not comply with the study requirements, or persons with severe physical or mental disabilities that may affect the completion of the study.~* Voluntary refusal to study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: t

Study Arms:
- Phase 1 Adult-vaccine (A Sample, blind study) (Type: EXPERIMENTAL): Group 1 (phase 1): 22 volunteers aged 18-50 years who will be the QazCovid-in® - COVID-19 twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
- Phase 1 Adult-Placebo (A Sample, blind study) (Type: PLACEBO_COMPARATOR): Group 2 (phase 1): 22 volunteers aged 18-50 years who will be the Placebo twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
- Phase 2 Adult-Vaccine, twice vaccination (An Open study) (Type: EXPERIMENTAL): Group 3 (phase 2): 50 volunteers aged 18-50 years who will be the QazCovid-in® - COVID-19 twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
- Phase 2 Elderly-Vaccine, twice vaccination (An Open study) (Type: EXPERIMENTAL): Group 4 (phase 2): 50 volunteers from 18 years old and elder who will be the QazCovid-in® - COVID-19 twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
- Phase 2 Adult-Vaccine, single vaccination (An Open study) (Type: EXPERIMENTAL): Group 5 (phase 2): 50 volunteers from 18 years old and elder who will be the QazCovid-in® - COVID-19 single vaccination, intramuscularly, at a dose of 0.5 ml volunteers from 18 years old and elder
- Phase 2 Elderly-Vaccine, single vaccination (An Open study) (Type: EXPERIMENTAL): Group 6 (phase 2): 50 vvolunteers from 18 years old and elder who will be the QazCovid-in® - COVID-19 single vaccination, intramuscularly, at a dose of 0.5 ml

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete